Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Buxtehude – page 36

1 242 clinical trials in Buxtehude, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Buxtehude at a glance
1 242
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 242 trials in Buxtehude

Open in trial search

Long-term Safety Study of CRISPR CAR T Cell Therapy for Patients with Blood and Solid Cancers

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Evoncabtagene pazurgedleucel
  • Sponsor:CRISPR Therapeutics AG

Chondrosarcoma

Recruiting

Study of ivosidenib in adults with advanced or metastatic chondrosarcoma with IDH1 mutation who are untreated or have had one prior treatment

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Study on Stopping Esomeprazole in Patients with Liver Cirrhosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study of Lenvatinib, Pembrolizumab, and Chemotherapy Combination for Patients with Advanced Esophageal Cancer Previously Treated with PD-1/PD-L1 Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Effects of Sparsentan for Children with Proteinuric Kidney Diseases

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Sparsentan
  • Sponsor:Travere Therapeutics Inc.

Colitis ulcerative+2

Recruiting

Study on the Long-term Safety of Guselkumab for Children with Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Study of TL-895 for Patients with Relapsed or Refractory Myelofibrosis or Indolent Systemic Mastocytosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Flixebrutinib
  • Sponsor:Telios Pharma Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Buxtehude

What the registry says about research in the country

01 Inflammatory Skin Conditions

Clinical trials focusing on moderate to severe atopic dermatitis and plaque psoriasis, evaluating novel treatments including amlitelimab, eblasakimab, and ESK-001. Research aims to assess treatment efficacy and long-term safety profiles.

  • Atopic Dermatitis Studies
  • Psoriasis Research
  • Treatment Response Assessment

Multiple studies examining maintenance therapy and dose optimization in chronic skin conditions.

02 Melanoma Research

Comprehensive studies evaluating advanced melanoma treatments, including adjuvant immunotherapy trials with pembrolizumab and novel combination therapies. Research focuses on both early-stage and metastatic disease.

  • Stage III/IV Melanoma
  • Immunotherapy Combinations
  • Disease-Free Survival

Emphasis on developing more effective treatment strategies for high-risk melanoma patients.

03 Rare Dermatological Conditions

Investigating treatments for chronic urticaria, hidradenitis suppurativa, and bullous pemphigoid. Studies evaluate innovative therapies including remibrutinib and dupilumab for these challenging conditions.

  • Chronic Urticaria Management
  • Autoimmune Skin Disorders
  • Novel Therapeutic Approaches

Focus on improving treatment outcomes for patients with resistant disease forms.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.